

Document Code:	DPOTMH-J-P11	
Effective Date:	12-31-2021	
Document Type:	Policy	
Page Number:	1 of 5	
Department/Section:	Pharmacy Division	
Document Title: ADVERSE DRUG REACTION AN ADVERSE DRUG EVENT REPOR		

PURPOSE:

- To establish a systematic monitoring and reporting procedure for adverse drug reactions (ADR) and adverse drug events (ADE) in order to avoid future drug related problems
- 2. To improve therapeutic outcomes by avoiding potential ADRs and ADEs
- 3. To provide guidelines on how to address ADRs and ADEs when they occur in order to maximize patient safety.

LEVEL:

All Physicians, Nurse, Pharmacists and other Healthcare Professionals

DEFINITION OF TERMS:

Adverse Drug Reaction- is a response to a drug which is noxious and unintended and which occurs at doses normally used for prophylaxis, diagnosis, or therapy of disease or for the modification of physiologic function.

These reactions include circumstances that:

- a) Requires discontinuing the drug (therapeutic or diagnostic)
- b) Requires changing the drug therapy
- c) Requires modifying the dose (except for minor dosage adjustments)
- d) Necessitates admission to a hospital
- e) Prolongs stay in a health care facility
- f) Necessitates supportive treatment
- g) Significantly complicates diagnosis
- h) Negatively affects prognosis
- i) Results in temporary or permanent harm, disability, or death

Adverse Drug Event - is an injury resulting from the use of a drug. Under this definition, the term ADE includes harm caused by the drug (adverse drug



Document Code:	DPOTMH-J-P11	
Effective Date:	12-31-2021	
Document Type:	Policy	
Page Number:	2 of 5	
Department/Section:	Pharmacy Division	
Document Title:	ADVERSE DRUG REACTION AND ADVERSE DRUG EVENT REPORTING	

reactions and overdoses) and harm from the use of the drug (including dose reductions, discontinuations of drug therapy and drug administration errors.)

High-risk Patient- includes but are not limited to pediatric patients, geriatric patients, patients with organ failure (e.g., hepatic or renal failure), and patients receiving multiple drugs.

Alerting Orders- include the use of "tracer" drugs that are used to treat common ADRs (e.g., orders for immediate doses of antihistamines, epinephrine, and corticosteroids), abrupt discontinuation or decreases in dosage of a drug, or stat orders for laboratory assessment of therapeutic drug levels.

POLICY:

- 1. It is the policy of Riverside Medical Center Inc. (RMCI) to establish a monitoring and reporting system for ADRs and ADEs. This system should establish the following:
 - 1.1. An ongoing and concurrent (during drug therapy) surveillance system based on the reporting of suspected ADRs by pharmacists, physicians, nurses, or patients.
 - 1.2. A prospective (before drug therapy) surveillance system for high-risk drugs or patients with a high risk for ADRs.
 - 1.3. A concurrent surveillance system for monitoring alerting orders. Alerting orders include the use of "tracer" drugs that are used to treat common ADRs (e.g., orders for immediate doses of antihistamines, epinephrine, and corticosteroids), abrupt discontinuation or decreases in dosage of a drug, or stat orders for laboratory assessment of therapeutic drug levels.
- 2. The data collected will aid the Pharmacy and Therapeutics Committee (PTC) in its assessment of drug use, individual patient incidents related to drug use, and drug



Document Code:	DPOTMH-J-P11	
Effective Date:	12-31-2021	
Document Type:	Policy	
Page Number:	3 of 5	
Department/Section:	Pharmacy Division	
Document Title:	ADVERSE DRUG REACTION AND ADVERSE DRUG EVENT REPORTING	

interactions, and will provide the basis for medical and nursing staff education that may minimize the occurrence of adverse reactions.

- 3. The fundamental role of this reporting system is to enhance patient safety by learning from failures of the healthcare system.
- 4. Monitoring for ADRs and ADEs is implemented throughout the duration of the patient's hospital stay.



Document Code:	DPOTMH-J-P11	
Effective Date:	12-31-2021	
Document Type:	e: Policy	
Page Number:	4 of 5	
Department/Section:	Pharmacy Division	
Document Title: ADVERSE DRUG REACTION A ADVERSE DRUG EVENT REPO		

	Name/Title	Signature	Date
Prepared by:	STEPHANIE CAMILLE O. SAMONTE, RPh. Inpatient Clinical Pharmacist	Suly	01/4/22
Verified:	MA. MADELYN N. LACSON, RPh., RN Inpatient Pharmacy Supervisor	Starlyn	1/11/22
	MIRIAM HOPE D. BRAVO, RPh. Inpatient Pharmacy Manager	rudbar	1/11/22
Reviewed by:	DENNIS C. ESCALONA, MN, FPCHA, FPSQua Quality Assurance Supervisor	2	61/11/2022
Recommending	PRINCESS M. ABELLON, MBA Pharmacy Division Officer	muey	1/11/2022
Approval:	HENRY F. ALAVAREN, MD, FPSMID, FPSQua Total Quality Division Head	Freuer	1/12/2027
Approved:	GENESIS GOLDI D. GOLINGAN President and CEO		2/12/22



Document Code:	DPOTMH-J-P11	
Effective Date:	12-31-2021	
Document Type:	Policy	
Page Number:	5 of 5	
Department/Section:	Pharmacy Division	
Document Title: ADVERSE DRUG REACTION AN ADVERSE DRUG EVENT REPOR		

DOCUMENTATION:

Revised Policy

DISSEMINATION:

Policies and Procedures Manual

REFERENCE:

University of Toledo "Adverse Drug Reaction Reporting Policy" 2019

Qmentum International "Medication Management" 2016

ASHP Guideline on Adverse Drug Reaction Monitoring and Reporting w]



Document Code:	DPOTMH-J-P11-S01	
Effective Date:	05-01-2022	
Document Type:	Standard Operating Procedure	
Page Number:	1 of 7	
Department/Section:	Pharmacy Division	
Document Title:	ADVERSE DRUG REACTION AND ADVERSE DRUG EVENT REPORTING	

PURPOSE:

To discuss the processes involved in the reporting of adverse drug reactions.

SCOPE:

Applies to all Pharmacy Division staff of Dr. Pablo O. Torre Memorial Hospital

PERSON RESPONSIBLE:

Clinical Pharmacists, Nurses, Physicians, Clinical Department Heads, Managers, Clinical Coordinator and Clinical Staff

GENERAL GUIDELINES:

- 1. Monitoring for ADRs and ADEs is done for all patients admitted to Dr. Pablo O. Torre Memorial Hospital.
- Clinical Department Heads, Managers, Clinical Coordinator shall schedule and facilitate clinical staff attendance on the training regarding the reporting of ADRs and ADEs.
- 3. Compliance to the procedure outlined in this document shall be ensured.

PROCEDURE:

- Upon admission, high-risk patients are identified by thorough assessment either
 by the admitting physician or attending physician. These assessments are to be
 recorded in the patient's medical record (e.g. in the patient's Clinical Data/Medical
 History, Doctor's Progress Notes).
- 2. The Pharmacist-on-the-floor in coordination with the Nursing Service Division and Medical Staff shall observe pharmacovigilance practices. Profiles of high-risk patients and alerting orders are to be double-checked prior to filling of



Document Code:	DPOTMH-J-P11-S01	
Effective Date:	05-01-2022	
Document Type:	Standard Operating Procedure	
Page Number:	2 of 7	
Department/Section:	Pharmacy Division	
Document Title:	ADVERSE DRUG REACTION AND ADVERSE DRUG EVENT REPORTING	

prescriptions and medication administration. Risk factors and potential for ADRs and ADEs are also double-checked and these includes:

- 2.1. Medication trough levels
- 2.2. Drug Allergies
- 2.3. Patient's laboratory values and records
- 2.4. Double-checking High-alert medication orders
- In accordance with the hospital's policy on Medication Reconciliation, the patient's medication profile should be timely reconciled in order to minimize the risk for ADEs involving medication duplications, medication discontinuation and inappropriate doses.
- 4. Whenever an ADR or ADE occurs, any member of the medical, nursing, or pharmacy staff may initiate the report using the ADR/ADE report form (Appendix A).
- 5. The report should be initiated within 24 hours after the reaction is recognized and must be completely filled as much as possible.
- 6. The information on the report form will include:
 - 6.1. Date of Report
 - 6.2. Date of Reaction/Date of Event
 - 6.3. Patient Location/Nursing Unit
 - 6.4. Patient Name
 - 6.5. Diagnosis (if known)
 - 6.6. Known allergies/hypersensitivities
 - 6.7. Drug suspected of causing reaction.
 - a) Complete name of the drug (generic and brand)
 - b) Manufacturer
 - c) Batch and Lot Numbers of suspected drug
 - 6.8. For ADE- circumstance of the event (e.g. administration error)
 - 6.9. Dose given and date/time dose given
 - Other concurrent drugs used within 24 hours (i.e., prescription, OTC, herbal, etc.)
 - 6.11. Description of reaction



Document Code:	DPOTMH-J-P11-S01	
Effective Date:	05-01-2022	
Document Type:	Standard Operating Procedure	
Page Number:	3 of 7	
Department/Section:	Pharmacy Division	
Document Title: ADVERSE DRUG REACTION A ADVERSE DRUG EVENT REPO		

- 6.12. Treatment of reaction and response
- 6.13. Reporter's ID number and signature
- 6.14. Attending Physician's Verification (name and signature)
- 6.15. Pharmacist's verification (name and signature)
- 7. The clinician who witnessed the reaction and initiated the report must notify the attending physician regarding the nature of the reaction.
- 8. The physician will examine the individual, order necessary intervention, if needed, and will complete the medical section of the Adverse Drug Reaction Report. The attending physician and direct care clinicians (e.g. residents and nurses) are to record the ADR or ADE in the patient's chart.
- 9. The ADR and ADE Report form is then documented and compiled by the Inpatient Pharmacy Department.
- 10. The Pharmacy Division in coordination with the Pharmacy and Therapeutics Committee (PTC) should review and analyze the reports and make programs to address problems identified (e.g. Training program on high-risk medications such as high-alert medications).
- 11. The PTC will review adverse drug reactions that have been reported to the Pharmacy. One or more of the following actions may be taken:
 - 11.1. The information may be provided to the manufacturer if the adverse reaction is not well known, or if the drug was only recently released for use.
 - 11.2. Medical or Nursing Staff may be informed of the reaction as part of the educational function of the Pharmacy, and of the PTC. Related information (recommended treatment of the reaction, ways to avoid the reaction, etc.) will also be provided. This will be done by a memo, the Drug Information bulletin, Medical Staff Bulletin, or other means.
 - 11.3. Depending on the nature of the reaction and its frequency, a drug utilization review may be initiated, and the committee may re-evaluate the inclusion of the drug in the Hospital Formulary.
 - 11.4. Depending on the severity and type of reaction, a report should be filed with the Food and Drug Administration (FDA).



Document Code:	DPOTMH-J-P11-S01	
Effective Date:	05-01-2022	
Document Type:	Standard Operating Procedure	
Page Number:	4 of 7	
Department/Section:	Pharmacy Division	
Document Title:	ADVERSE DRUG REACTION AND ADVERSE DRUG EVENT REPORTING	

11.5. Any other actions that may reduce the risk of recurrence of the adverse reaction, or serve to educate the nursing and medical staff.

REFERENCE:

University of Toledo "Adverse Drug Reaction Reporting Policy" 2019

Qmentum International "Medication Management" 2016

ASHP Guideline on Adverse Drug Reaction Monitoring and Reporting



Document Title: ADVERSE DRUG REACTION ADVERSE DRUG EVENT REPO		
Department/Section:	Pharmacy Division	
Page Number:	5 of 7	
Document Type:	Standard Operating Procedure	
Effective Date:	05-01-2022	
Document Code:	DPOTMH-J-P11-S01	

	Name/Title	Signature	Date
Prepared by:	STEPHANIE CAMILLE O. SAMONTE, RPh. Inpatient Clinical Pharmacist	den	5-2-22
	MA. MADELYN N. LACSON, RPh., RN Inpatient Pharmacy Supervisor	Senselyn	slyl
Verified:	MIRIAM HOPE D. BRAVO, RPh. Inpatient Pharmacy Manager	udhar	5/4/2
Reviewed by:	DENNIS C. ESCALONA, MN, FPCHA, FPSQua Quality Assurance Supervisor	2	5/5/2012
Recommending	PRINCESS M. ABELLON, MBA Pharmacy Division Officer	amely	5/5/2022
Approval:	HENRY F. ALAVAREN, MD, FPSMID, FPSQua Total Quality Division Head	theen	T/19/20m
Approved:	GENESIS GOLDI D. GOLINGAN President and CEO		6/0/22



Document Code:	DPOTMH-J-P11-S01	
Effective Date:	05-01-2022	
Document Type:	Standard Operating Procedure	
Page Number:	6 of 7	
Department/Section:	Pharmacy Division	
Document Title:	ADVERSE DRUG REACTION AND ADVERSE DRUG EVENT REPORTING	

ANNEX A:

Owner and Operat	MEDICAL CEN for of the Dr. Pablo O. Torre Ment or of the Metro Pacific Hospital Ho	norial Hospital		
I HONTEAG		SEX		
		G REACTION REPOR		
REPORT ANY REACTION	OR INCIDENCE THAT MAY UNINTENDED IN	DOSES ACCEPTED IN MEDI	ICAL PRACTICE.	
ate of Reaction:	Time of Reaction		ocation Reaction Occurr	
uspected Cause: (Brand Nam		(Generic Name) Number:	Batala Massa	Start Date:
lanufacturer:	Lot	Number:	Batter Paul	ber:
oncurrent Drugs:		N/A 16	· ·	
las patient ever received this			.ну:	
ny past reaction noted? Ye		s, specify:		
fanifestation of Past Reaction				
Inown Allergies/Sensitivities				
	Check app	ropriate box(es) sympto		
NEURO:	RESPIRATORY:	GI:	CNSt	SKIN:
Dizziness	□ Dyspnea	□ Nausea	☐ Headache	☐ Rash Site (s) & Type
Confusion Paresthesia (location)	(rate)	□ Vomiting □ Diarrhea	☐ Confusion ☐ Anxiety	
Parestnesia (location)	(rate)	□ Constipation	Sedation	□ Alopecia
Tingling (location)	☐ Shallow, slow	□ Melena	☐ Depression	Sloughing-necrosis
- 10	Orthopnea	GI Upset	□ Malaise	□ Itching □ Flushing
□ Change in Consciousness □ Tinnitus	□ Bronchospasm	☐ GI Pain	CV:	Swelling
☐ Hearing Acuity	RENAL:	LABS:	Hypertension	□ Phlebitis
Fever	□ Hematuria	□ LFTs □ Scr/BUN	☐ Hypotension ☐ Chest Pain	□ Erythema
Chills	□ Oliguria	□ Neutropenia	Arrhythmias	
	□ Anuria	□ Anemia	☐ Bradycardia	
Others:		□ Electrolyte	□ Tachycardia	
Others:		DS		hills
Joint Pain (location):			Vheezing S	ieizures
Edema (Incation):		OF	ever 🗆 5	ihack
Vas the Physician Notified: 🗆 Yo				
Describe Therapy or Treatment In	nitiated:			
esponse to Treatment/Outcome	of Incident:			
Completed by:			Veril	fied by:
	nature)		(Physician Full	Name/Signature/Stamp)
(Pharmacist Full Name/Sign				
(Pharmacist Full Name/Sign DPOTMH-PHARM-F009 (R1) Effective Date: 04-01-2022		Unaut	thorized duplication of this for	m is strictly prohibited



Document Code:	DPOTMH-J-P11-S01	
Effective Date:	05-01-2022	
Document Type:	Standard Operating Procedure	
Page Number:	7 of 7	
Department/Section:	Pharmacy Division	
Document Title:	ADVERSE DRUG REACTION AND ADVERSE DRUG EVENT REPORTING	

ANNEX B:



RIVERSIDE MEDICAL CENTER, INC.

Owner and Operator of the Dr. Pablo O. Torre Memorial Hospital A proud member of the Metro Pacific Hospital Holdings, Inc.

ADVERSE DRUG EVENT REPORT

DATE OCCURRED	DRUG INVOLVED	SEVERITY LEVEL	PREVENTABILITY LEVEL	REPORTED PATIENT REACTION/SYMPTOMS	TREATMENT ORDERED	PATIENT OUTCOME

Severity (S) Levels:

- No action necessary, reaction minor
- Change prescription, no treatment necessary
- 3. Change prescription, treatment instituted
- Change prescription, provide treatment, requires admission or longer LOS
 Change prescription, provide treatment, requires transfer to higher acuity unit (ICU/CCU)
- 6. Change prescription, provide treatment, results in irreversible harm/injury
- 7. Results in death

Preventability (P) Levels:


- 1. Unpreventable, Rx appropriate for disea
- 2. Possibly preventable, different Rx could be ordered 3. Possibly preventable, drug-drug interaction noted
- Possibly preventable, food-drug interaction noted
 Preventable, documented patient allergy
- 6. Preventable, drug known to cause toxicity- no levels obtained
- Preventable, drug known to cause toxicity continuous monitoring required not performed
- 8. Preventable, drug ordered inappropriate for patient disease

Recommendations: (Pharmacy Only) Verified By: Completed By: (Complete Name/Signature/Badge Number//Date) (Complete Name/Signature/Badge Number/Date) DPOTMH-PHARM-F008 Unauthorized duplication of this form is strictly prohibited Effective Date: 02-01-2020

B.S. Aquino Drive, Bacolod City, Neg. Occ. 6100, Philippines • www.rivermedcenter.net (034) 705-0000 / (034) 433-7331




Document Code:	DPOTMH-J-P11-FC01	
Effective Date:	05-01-2022	
Document Type:	Flowchart	
Page Number:	1 of 3	
Department/Section:	Pharmacy Division	
Document Title:	ADVERSE DRUG REACTION AND ADVERSE DRUG EVENT REPORTING	





Document Code:	DPOTMH-J-P11-FC01	
Effective Date:	05-01-2022	
Document Type:	Flowchart	
Page Number:	2 of 3	
Department/Section:	Pharmacy Division	
Document Title:	ADVERSE DRUG REACTION AND ADVERSE DRUG EVENT REPORTING	





Document Code:	DPOTMH-J-P11-FC01	
Effective Date:	05-01-2022	
Document Type:	Flowchart	
Page Number:	3 of 3	
Department/Section:	Pharmacy Division	
Document Title:	ADVERSE DRUG REACTION AND ADVERSE DRUG EVENT REPORTING	

	Name/Title	Signature	Date
Prepared by:	STEPHANIE CAMILLE O. SAMONTE, RPh. Inpatient Clinical Pharmacist	Que lo	5-2-22
V:C-1	MA. MADELYN N. LACSON, RPh., RN Inpatient Pharmacy Supervisor	Linkolyn	slyh
Verified:	MIRIAM HOPE D. BRAVO, RPh. Inpatient Pharmacy Manager	udhor	5/4/20
Reviewed by:	DENNIS C. ESCALONA, MN, FPCHA, FPSQua Quality Assurance Supervisor	2	5/5/2022
Recommending	PRINCESS M. ABELLON, MBA Pharmacy Division Officer	muy	5/5/2022
Approval:	HENRY F. ALAVAREN, MD, FPSMID, FPSQua Total Quality Division Head	Druen	Mochella
Approved:	GENESIS GOLDI D. GOLINGAN President and CEO	#8	6/10/22



Document Code:	DPOTMH-J-P11-WI01	
Effective Date:	05-01-2022	
Document Type:	Work Instruction	
Page Number:	1 of 3	
Department/Section:	Pharmacy Division	
Document Title:	ADVERSE DRUG REACTION AND ADVERSE DRUG EVENT REPORTING	

KEY TASKS	PERSON RESPONSIBLE
1. Identifies high-risk patients by performing thorough assessment.	Admitting Physician or Attending Physician
2. Records the assessment in the patient's medical record.	Admitting Physician or Attending Physician
3. Observes pharmacovigilance practices	Pharmacist-on-the-floor and Nurse
4. Reconciles the patient's medication profile to minimize the risks	Physician/ Pharmacist/ Nurse
5. Monitors patient for possible ADRs and ADEs	Nurse
6. Initiates the report using the ADR/ ADE	Clinician who witnessed the reaction (any member of the Medical, Nursing, or Pharmacy Staff)
7. Notifies the attending physician regarding the nature of the reaction	Clinician who witnessed the reaction (any member of the Medical, Nursing, or Pharmacy Staff)
8. Examines the individual, order necessary intervention, if needed, and completes the medical section of the Adverse Drug Reaction Report	Physician
9. Documents and compiles the ADR and ADE Report Form	Inpatient Pharmacist
10.Reviews the severity and occurrence of ADRs and ADEs and design programs to minimize the risk	Pharmacy and Therapeutics Committee



Document Code:	DPOTMH-J-P11-WI01	
Effective Date:	05-01-2022	
Document Type:	Work Instruction	
Page Number:	2 of 3	
Department/Section:	Pharmacy Division	
Document Title:	ADVERSE DRUG REACTION AND ADVERSE DRUG EVENT REPORTING	

of ADRs and ADEs in the future	
11. Coordinates with the FDA regarding guidelines on how to address ADRs and ADEs especially for new drugs (those that have not been on the market for more than 3 years).	Pharmacy and Therapeutics Committee
12. Verifies reports regarding ADRs and ADEs and coordinate with the Nursing Department and medical staff in monitoring patients for possible ADRs and ADEs	Pharmacists
13. Provides therapeutic advice in an event an ADR or ADE occurs (e.g. dosage adjustments, therapeutic alternatives).	Pharmacists
14. Educates the healthcare staff regarding medications that are high-risk for ADRs and ADEs (e.g. High Alert Medications)	Pharmacists
15. Ensures compliance to the procedure outlined in the policy on Adverse Drug Reaction and Adverse Drug Reporting.	Clinical Department Heads Managers, Clinical Coordinator and Clinical Staff
16. Schedules and facilitates clinical staff attendance on the training regarding the reporting of ADRs and ADEs.	Clinical Department Heads Managers, Clinical Coordinator and Clinical Staff



Document Code:	DPOTMH-J-P11-WI01	
Effective Date:	05-01-2022	
Document Type:	Work Instruction	
Page Number:	r: 3 of 3	
Department/Section:	/Section: Pharmacy Division	
Document Title:	ADVERSE DRUG REACTION AND ADVERSE DRUG EVENT REPORTING	

	Name/Title	Signature	Date
Prepared by:	STEPHANIE CAMILLE O. SAMONTE, RPh. Inpatient Clinical Pharmacist	Soll	5-2-22
Verified:	MA. MADELYN N. LACSON, RPh., RN Inpatient Pharmacy Supervisor	Haddy	stthe
	MIRIAM HOPE D. BRAVO, RPh. Inpatient Pharmacy Manager	nedhow	5/4/22
Reviewed by:	DENNIS C. ESCALONA, MN, FPCHA, FPSQua Quality Assurance Supervisor	2	1/1/2022
Recommending Approval:	PRINCESS M. ABELLON, MBA Pharmacy Division Officer	maj	5k/2022
	HENRY F. ALAVAREN, MD, FPSMID, FPSQua Total Quality Division Head	Myen	J/19/2012
Approved:	GENESIS GOLDI D. GOLINGAN President and CEO		6/15/2